索拉非尼联合TACE治疗晚期原发性肝癌的临床观察

Effect of combined Sorafenib and transarterial chemoembolization on advanced primary hepatocellular carcinoma

摘要: 目的观察索拉非尼联合经导管肝动脉化疗栓塞(TACE)治疗晚期原发性肝癌(HCC)的疗效及不良反应。方法回顾性分析本院口服索拉非尼1个月以上并行TACE治疗的65例晚期原发性肝癌患者,按照RECIST标准对其疗效进行评价,并记录不良反应发生情况。结果患者总体存活率为66.2%,存活43例中31例疾病稳定,部分缓解7例,疾病控制率为88.4%。不良反应发生率为78.5%,经对症处理后绝大多数明显缓解。结论索拉非尼联合TACE治疗晚期HCC安全有效。

Abstract: Objective To observe the effect and side effects of combined Sorafenib and transarterial chemoembolization（TACE） on advanced primary hepatocellular carcinoma（HCC）. Methods Therapeutic effects of combined oral Sorafenib and TACE for over 1 month on advanced primary HCC in 65 patients admitted to our hospital were retrospectively analyzed according to the RECIST criteria and the side effects were recorded. Results The overall survival rate of the patients was 66.2%.Among the 43 survived patients,HCC was stable in 31 and partially remitted in 7,with a disease control rate of 88.4% and an adverse reaction rate of 78.5%.The disease was significantly relieved after expectant treatment. Conclusion Combined Sorafenib and TACE therapy is safe and effective for advanced primary HCC.